• 1
    Volberding, PA, Lagakos, SW, Grimes, JM et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333, 401 407.
  • 2
    Concorde Co-ordinating Committee. Concorde. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343, 871 881.
  • 3
    Hammer, SM, Katzenstein, DA, Hughes, MD et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335, 1081 1090.
  • 4
    Saravolatz, LD, Winslow, DL, Collins, G et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimetre. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1996; 335, 1099 1106.
  • 5
    Delta Co-ordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348, 283 291.
  • 6
    Hammer, SM, Squires, KE, Hughes, MD et al. A controlled trial of two nucleoside analogues plus indinavir in people with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337, 725 733.
  • 7
    Gulick, RM, Mellors, JW, Havlir, D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337, 734 739.
  • 8
    Spira, R, Marimoutou, C, Binquet, C, Lacoste, D, Dabis, F, For The Groupe d'epidémiologie Clinique du, SIDA. en Aquitaine (GECSA). Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients. France, 199597 J Acquir Immune Defic Syndr 1998; 18, 358 364.
  • 9
    Egger, M, Hirschel, B, Francioli, P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315, 1194 1199.
  • 10
    Mocroft, A, Vella, S, Benfield, TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352, 1725 1730.
  • 11
    Palella, Fj Jr, Delaney, KM, Moorman, AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338, 853 860.
  • 12
    Detels, R, Muñoz, A, McFarlane, G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 17, 1497 1503.
  • 13
    Uk Register of, HIV & Seroconverters Steering Committee. The, AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS 1998; 12, 659 667.
  • 14
    Dorrucci, M, Balducci, M, Pezzotti, P et al. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. J AIDS 1999; 22, 65 70.
  • 15
    Pedersen, C, Lindhardt, BØ, Jensen, BØ et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299, 154 157.
  • 16
    Touloumi, G, Karafoulidou, A, Gialeraki, A et al. Determinants of progression of HIV infection in a Greek haemophilia cohort followed for up to 16 years after infection. J AIDS 1998; 19, 89 97.
  • 17
    Schwartländer, B, Bek, B, Skarabis, H et al. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. AIDS 1993; 7, 813 821.
  • 18
    Marimoutou, C, Chene, G, Dabis, F, Lacoste, D, Salamon, R, For The Groupe d'epidemiologie Clinique du, SIDA. en Aquitaine (GECSA). Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system. 198595 Presse Med 1997; 26, 703 710. [in French].
  • 19
    Carré, N, Meyer, L, Boufassa, F et al. and the SEROCO Study Group. High risk of HIV disease progression after infection through a sexual partner with AIDS. AIDS 1996; 10, 77 80.
  • 20
    Pezzotti, P, Phillips, AN, Dorrucci, M et al. Category of exposure to HIV and age in the progression to AIDS. longitudinal study of 1199 people with known dates of seroconversion. BMJ 1996; 313, 583 586.
  • 21
    Van Den Hoek, JAR, Coutinho, RA, Van Haastrecht, HJA et al. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988; 2, 55 60.
  • 22
    Van Griensven, GJP, Tielman, RAP, Goudsmit, J et al. Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987; 125, 1048 1057.
  • 23
    Eskild, A, Magnus, P, Brekke, T et al. The impact of exposure group on the progression rate to acquired immunodeficiency syndrome. Scand J Infect Dis 1997; 29, 103 109.
  • 24
    Dobloug, JH, Bruun, JN, Skaug, K. The early introduction of HIV infection among Norwegians at highest risk. Scand J Infect Dis 1990; 22, 753 754.
  • 25
    Montoro, JB, Oliveras, J, Lorenzo, JI et al. An association between clotting factor concentrates use and mortality in human immunodeficiency virus-infected haemophilic patients. Blood 1995; 86, 2213 2219.
  • 26
    Grupo de estudio de seroconvertores, CAM. Identificación de factores que afectan a la historia natural de la infección por el VIH en una cohorte de personas con fecha de seroconversión conocida. Santiago de Compostela, SEISIDA, 1999 CP5–7.
  • 27
    Perez-Hoyos, S, Avino, M, Hernandez, I et al. AIDS-free time and survival of an injecting drug users HIV seroconverters cohort. Gac Sanit 1999; 13, 337 345.
  • 28
    Brettle, RP, McNeil, AJ, Burns, S et al. Progression of HIV. Follow-Up of Edinburgh Injecting Drug Users with Narrow Seroconversion Intervals In 198385 AIDS 1996; 10, 419 430.
  • 29
    Sabin, CA, Devereux, H, Phillips, AN et al. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 1998; 12, 1347 1352.
  • 30
    Tindall, B, Swanson, CE, Cooper, DA. Development of AIDS in a cohort of HIV-seropositive homosexual men in Australia. Med J Aust 1990; 153, 260 265.
  • 31
    Vanhems, P, Allard, R, Cooper, A et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive. Clin Infect Dis 1997; 24, 965 970.
  • 32
    Kaplan, EL & Meier, P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53, 457 481.
  • 33
    Clayton, C & Hills, M. Statistical Models in Epidemiology. Oxford. Oxford University Press, 1993.
  • 34
    Vanhems, P, Lambert, J, Cooper, DA et al. Acute HIV-1 illness severity and prognosis: a dose response effect. Clin Infect Dis 1998; 26, 323 329.
  • 35
    Lindbäck, S, Broström Karlsson, A, Gaines, H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 106/l, AIDS, and death from AIDS? BMJ 1994; 309, 1535 1537.
  • 36
    Keet, IPM, Krijnen, P, Koot, M et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7, 51 57.
  • 37
    Cox, DR. Regression models and life tables. J R Stat Soc 1972; 34, 187 220.
  • 38
    Huber, PJ. The behavior of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley: University of California Press, 1967: 221 233.
  • 39
    Durrelman, S & Simon, R. Flexible regression models with cubic splines. Stats Med 1989; 8, 551 561.
  • 40
    Junghans, C, Low, N, Chan, P et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13, 2547 2554.
  • 41
    Phillips, AN, Lee, CA, Elford, J et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991; 4, 970 975.
  • 42
    Prins, M, Robertson, JR, Brettle, RP et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13, 2361 2443.